On Monday, Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) trading session started at the price of On Monday, that was -5.56% drop from the session before settling in for the closing price of $1.26. A 52-week range for ZNTL has been $1.01 – $5.44.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -12.89% over the last five years. When this article was written, the company’s average yearly earnings per share was at 1.13%. With a float of $55.51 million, this company’s outstanding shares have now reached $71.95 million.
The firm has a total of 166 workers. Let’s measure their productivity. In terms of profitability, gross margin is 97.6%, operating margin of -789.32%, and the pretax margin is -834.36%.
Zentalis Pharmaceuticals Inc (ZNTL) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Zentalis Pharmaceuticals Inc stocks. The insider ownership of Zentalis Pharmaceuticals Inc is 22.85%, while institutional ownership is 76.44%. The most recent insider transaction that took place on Apr 30 ’25, was worth 29,373. In this transaction Director of this company bought 21,000 shares at a rate of $1.40, taking the stock ownership to the 281,192 shares. Before that another transaction happened on Feb 06 ’25, when Company’s Chief Medical Officer bought 20,000 for $2.28, making the entire transaction worth $45,656. This insider now owns 36,629 shares in total.
Zentalis Pharmaceuticals Inc (ZNTL) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 1.13% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 5.90% during the next five years compared to -12.89% drop over the previous five years of trading.
Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) Trading Performance Indicators
You can see what Zentalis Pharmaceuticals Inc (ZNTL) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 6.94. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.19.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.15, a number that is poised to hit -0.55 in the next quarter and is forecasted to reach -2.06 in one year’s time.
Technical Analysis of Zentalis Pharmaceuticals Inc (ZNTL)
Analysing the last 5-days average volume posted by the [Zentalis Pharmaceuticals Inc, ZNTL], we can find that recorded value of 1.14 million was lower than the volume posted last year of 1.36 million. As of the previous 9 days, the stock’s Stochastic %D was 41.03%.
During the past 100 days, Zentalis Pharmaceuticals Inc’s (ZNTL) raw stochastic average was set at 11.08%, which indicates a significant decrease from 14.63% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 82.67% in the past 14 days, which was lower than the 83.97% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.3268, while its 200-day Moving Average is $2.3278. Now, the first resistance to watch is $1.2433. This is followed by the second major resistance level at $1.2967. The third major resistance level sits at $1.3433. If the price goes on to break the first support level at $1.1433, it is likely to go to the next support level at $1.0967. Now, if the price goes above the second support level, the third support stands at $1.0433.
Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) Key Stats
There are 71,952K outstanding shares of the company, which has a market capitalization of 85.62 million. As of now, sales total 67,430 K while income totals -165,840 K. Its latest quarter income was 26,870 K while its last quarter net income were -47,470 K.
